MedTrace Logo

Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia

NCT00735813 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2012-09-05

No results posted yet for this study

Summary

Children with cancer need a long term tunnelled central venous catheter (TCVC) for the entire duration of their treatment. TCVCs are locked with heparin when not in use. The most frequent complications of long term TCVC are catheter related blood steam infections. Taurolock is a new lock that is claimed to prevent the formation of luminal biofilm in TCVCs and has been demonstrated to eradicate infected CVCs. In this study the investigators will compare TCVCs locked with heparin with TCVCs locked with Taurolock. Hypothesis: Taurolock will diminish the number of CRBSI in children with cancer compared with children with heparin lock of their CVC.

Conditions

  • Bacteremia
  • Neoplasms

Interventions

DEVICE

Taurolock

When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.

DEVICE

Heparin

When not in use the childrens tunneled central venous catheters are locked with heparin

Sponsors & Collaborators

  • Danish Child Cancer Foundation

    collaborator OTHER

  • TauroPharm

    collaborator INDUSTRY

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Henrik Schrøder, MD, Dr.med. · Aarhus Universityhospital, Skejby

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Denmark

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00735813 on ClinicalTrials.gov